For adult patients with chronic rhinosinusitis (CRS) following ethmoid, frontal, or maxillary sinus surgery

The PROPEL family of sinus implants reduced the need for post-operative intervention vs a non-drug implant. For example, PROPEL Contour reduced the need for postoperative interventions by 65% vs surgery alone, at 30 days following frontal sinus surgery.


PROPEL is a bioabsorbable stent placed following sinus surgery to keep the sinus open using a spring-like mechanism. The stent delivers steroid medication to the sinus tissue for up to 30 days. Over time, it dissolves on its own, so removal isn’t required, but the doctor can remove it at any time. PROPEL has been proven to reduce inflammation/edema and the need for oral steroids. In clinical studies, patients using PROPEL needed less post-surgery intervention at 30 days compared with patients not using PROPEL.

The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at Rx only.